Fig 1.
Physician answers (n =53) to National Oncology Positron Emission Tomography (PET) Registry questionnaires concerning extent of disease and the impact of fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) PET/computed tomography (CT) on clinical management. Responses were confirmed by medical record review. (A) Responses to extent of disease on FDG-PET/CT compared with CT or magnetic resonance imaging (MRI). (B) Responses to FDG-PET/CT and avoidance of additional tests.